Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
NCT ID: NCT00685516
Last Updated: 2020-12-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
113 participants
INTERVENTIONAL
2007-09-01
2015-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase II trial is studying green tea to see how well it works compared with black tea and water in treating patients with prostate cancer undergoing surgery.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* to determine the effect of GT and BT consumption on apoptosis (TUNEL, ratio Bax:Bcl-2), proliferation, oxidation, and inflammation in malignant radical prostatectomy tissue compared to water control using immunohistochemistry.
* to examine levels of tea polyphenols and methylated tea polyphenol metabolites in fresh frozen radical prostatectomy tissue and urine, urinary oxidative DNA damage (8OHdG) and serum prostate-specific antigen (PSA) levels.
OUTLINE: This is a multicenter, randomized study. Patients are randomized to 1 of 3 treatment arms.
* Arm I: Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
* Arm II: Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
* Arm III: Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
Patients undergo radical prostatectomy.
Blood and urine samples, as well as tissue from diagnostic biopsy and radical prostatectomy specimens, are obtained for laboratory correlative studies. Samples are assessed by IHC, high-performance liquid chromatography, or mass spectrometry for changes in prostate tumor grade, stage, and margin status; concentrations of total and free tea polyphenols (i.e., EGCG, EC, EGC, ECG), theaflavins, and conjugated/colonic tea metabolites; biomarkers of prostate cancer development and progression (i.e., serum PSA, proliferation \[i.e., Ki-67\], apoptosis \[i.e., TUNEL, Bax/Bcl-2 ratio\], inflammation \[i.e., NFkB\]), and oxidative status (i.e., 8OhdG/dG ratio); and genotype and gene expression of metabolizing enzymes (i.e., COMT, UGT, and SULT). Serum samples are also assessed by ex vivo LNCaP cell culture assay for antiproliferative activity and by competitive chemiluminescent immunoassay for concentrations of PSA, IGF-1, IGFBP-3, testosterone, SHBG, and DHEA-sulfate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I - Green Tea
Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea
6 cups of green tea daily for 2-8 weeks
Arm II - Water
Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo
6 cups of water daily for 2-8 weeks
Arm III - Decaffeinated black tea
Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea
6 cups of decaffeinated black tea daily for 2-8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
green tea
6 cups of green tea daily for 2-8 weeks
placebo
6 cups of water daily for 2-8 weeks
decaffeinated black tea
6 cups of decaffeinated black tea daily for 2-8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* subject is 40-75 years of age and has a diagnosis of adenocarcinoma of the prostate.
* Scheduled to undergo radical prostatectomy.
* The subject agrees to stop consumption of tea or tea-containing products throughout the entire intervention period except for the tea provided during study intervention.
* The subject agrees to stop consumption of dietary or vitamin supplements (e.g., lycopene, Vitamin E, selenium, genistein) or herbal supplements (e.g., saw palmetto, PC-SPES)
Exclusion Criteria
* ongoing alcohol abuse
* significant medical or psychiatric conditions that would make the patient a poor protocol candidate
* prior sensitivity or allergic reaction to tea, tea products, or tea supplements
* allergy or sensitivity to multiple food items or nutritional supplements
* concurrent luteinizing hormone-releasing hormone agonists, androgen receptor blocking agents, or finasteride
* prior bilateral orchiectomy
40 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Jonsson Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne M. Henning, PhD, RD
Role: PRINCIPAL_INVESTIGATOR
Jonsson Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, United States
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015 Apr 1;75(5):550-9. doi: 10.1002/pros.22943. Epub 2014 Dec 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCLA-061109702
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000596162
Identifier Type: OTHER
Identifier Source: secondary_id
10-001050
Identifier Type: -
Identifier Source: org_study_id